ubiquinone has been researched along with Diabetes--Gestational* in 4 studies
1 trial(s) available for ubiquinone and Diabetes--Gestational
3 other study(ies) available for ubiquinone and Diabetes--Gestational
Article | Year |
---|---|
Intergenerational effects of the antioxidant Idebenone on the placentas of rats with gestational diabetes mellitus.
Experimental models of maternal diabetes lead to the intrauterine programming of Gestational Diabetes Mellitus (GDM) in the offspring, together with an intrauterine proinflammatory environment, feto-placental metabolic alterations and fetal overgrowth. The aim of this work was to evaluate the effect of the mitochondrial antioxidant Idebenone given to F0 mild pregestational diabetic rats on the development of GDM in their F1 offspring and the intergenerational programming of a pro-oxidant/proinflammatory environment that affects the placentas of F2 fetuses. Control and mild pregestational diabetic female rats (F0) were mated with control males, and Idebenone or vehicle was administered to diabetic rats from day 1 of gestation to term. The F1 female offspring were mated with control males and maternal and fetal plasma samples were obtained for metabolic determinations at term. The F2 fetuses and placentas were weighed, and placental protein levels and peroxynitrite-induced damage (immunohistochemistry), mRNA levels (PCR), nitric oxide production (Griess reaction), and number of apoptotic cells (TUNEL) were evaluated. The F1 offspring of F0 diabetic rats (treated or not with Idebenone) developed GDM. The placentas of GDM rats showed a decrease in the mRNA levels of manganese superoxide dismutase and an increase in the production of nitric oxide, peroxynitrite-induced damage, and connective tissue growth factor levels, alterations that were prevented by the maternal Idebenone treatment in F0 rats. In conclusion, the maternal treatment with Idebenone in pregestational diabetic F0 rats ameliorates the pro-oxidant/proinflammatory environment that affects the placentas of F2 fetuses, although it does not prevent F1 rats from developing GDM. Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetes, Gestational; Female; Fetal Macrosomia; Fetus; Male; Nitric Oxide; Placenta; Pregnancy; Pregnancy Proteins; Rats; Rats, Wistar; Ubiquinone | 2021 |
Amniotic coenzyme Q10: is it related to pregnancy outcomes?
Coenzyme Q10 (CoQ10 or ubiquinone) is an essential component of the mitochondrial electron transport chain and is also present in various cellular membranes and in plasma lipoproteins. Diabetes, cardiovascular, neurodegenerative, and preeclampsia diseases are all associated with an alteration of CoQ10 level or its redox status. During pregnancy, we note that the plasma content of CoQ10 is significantly higher than amniotic. In the fetal growth restriction group, amniotic total CoQ10 levels were significantly higher versus healthy, while the amniotic oxygen radical absorbing capacity level was significantly lower. A significant negative correlation was observed between amniotic total CoQ10 and birthweight. Our observation leads to the hypothesis that the amniotic midtrimester CoQ10 content may be a marker of subsequent obstetric complications. Topics: Adult; Amniotic Fluid; Case-Control Studies; Diabetes, Gestational; Female; Fetal Growth Retardation; Fetal Membranes, Premature Rupture; Humans; Oxidative Stress; Pregnancy; Pregnancy Outcome; Reactive Oxygen Species; Risk Factors; Ubiquinone | 2014 |
Plasma coenzyme Q10 is increased during gestational diabetes.
To determine plasma CoQ(10) concentration in the course of gestational diabetes mellitus.. The assessment was provided longitudinally during the third trimester of pregnancy in 40 women with gestational diabetes mellitus (GDM) and 40 normal controls. CoQ(10) was measured with the HPLC method. CoQ(10) results were also normalized to plasma cholesterol concentration (nmoles/mmoles). Plasma samples were collected longitudinally throughout the third trimester.. No statistically significant difference of plasma CoQ(10)/cholesterol levels between GDM patients and controls at 28-32 and 32-36 weeks of gestation, this difference was significant in late pregnancy (36-40 weeks), similarly, in the same gestational period, there was an increased level of HOMA-IR as index of insulin resistance ORAC as index of oxidative stress.. Since coenzyme Q(10) is believed to be an important cellular antioxidant defence, higher levels of CoQ(10) in GDM patients may be a compensatory mechanism, in response to an activated oxidative stress, probably associated to hyperglycaemia and insulin resistance. Topics: Adult; Biomarkers; Blood Glucose; Case-Control Studies; Cholesterol; Chromatography, High Pressure Liquid; Diabetes, Gestational; Female; Humans; Insulin; Insulin Resistance; Italy; Longitudinal Studies; Oxidative Stress; Pregnancy; Pregnancy Trimester, Third; Ubiquinone | 2011 |